Onza

Quick links to important sections

Onza

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Onza

Quick Facts

Property Description
Active ingredient Olanzapine
Form Oral tablets (Film-coated, ODT), Intramuscular injection solution
Pharmacological class Atypical Antipsychotic (Second-Generation), Psychotropic Agent
Common purpose Stabilizing thought and mood in severe mental health conditions
Origin Synthetic, Thienobenzodiazepine derivative

What Type of Medicine is Onza?

Onza is a trade name for a prescription medication whose active substance is olanzapine, which is classified as an atypical antipsychotic drug. This medication is a psychotropic agent designed to help restore stability and normalize disrupted thought processes and severe mood states. Olanzapine is formally recognized as a second-generation antipsychotic, distinguished by its specific actions on chemical signaling in the brain. The compound is a synthetic molecule known as a thienobenzodiazepine derivative, a structure integral to its therapeutic function in the central nervous system. The agent is recognized for its role in promoting mental equilibrium and calming acute psychological distress, such as those experienced during a manic episode.


Onza’s Composition and Pharmaceutical Forms

The pharmaceutical preparation Onza is a synthetic, single-ingredient compound whose active component is olanzapine. This product is primarily supplied as an oral formulation, including both film-coated tablets and the orally disintegrating tablets (ODT). The availability of the ODT form represents a specific pharmaceutical feature, allowing for convenient intake. The medication is designed for oral intake, though olanzapine is also manufactured as a solution for intramuscular injection (IM), which is used for rapid, acute stabilization in clinical settings. These pharmaceutical forms are used to meet specific clinical requirements for the administration of the compound.


General Principle: How Olanzapine Stabilizes Mood

Olanzapine works by promoting psychological stability through the balancing of chemical messengers in the brain. The drug primarily influences the activity of key neurotransmitters, most notably dopamine and serotonin. By modulating these signals, olanzapine helps manage and relieve profound disturbances in thought and emotion, allowing patients to regain a more stable and controlled mental state. This simple principle of neurochemical modulation is the foundation of its general therapeutic benefit.

Regulatory References

  1. U.S. National Library of Medicine (NIH)
  2. European Medicines Agency (EMA)

What side effects are possible with Onza?

Possible Side Effects and Safety Information

The safety profile of Onza (olanzapine) is officially documented by regulatory agencies, detailing adverse reactions classified by frequency and affected body systems. These classifications guide the factual understanding of the medicine's risk profile.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their documented occurrence in clinical studies:

  • Very Common (ge 1/10): This tier includes somnolence (sleepiness), weight gain, and increases in plasma levels of prolactin, glucose, and triglycerides. These are the most frequently observed effects according to official regulatory data.
  • Common (ge 1/100 to < 1/10): Effects such as dizziness, constipation, dry mouth, tremor, and a drop in blood pressure upon standing (orthostatic hypotension) are documented in this category.

System-Organ-Class Safety Notes

The official label documents safety concerns primarily within the Metabolism and Nutrition system (due to changes in weight, glucose, and lipids) and the Nervous System (due to sedation and movement-related effects).

Serious Safety Considerations

Regulatory documents explicitly list rare but clinically significant adverse reactions. These include Neuroleptic Malignant Syndrome (NMS), a severe, potentially life-threatening reaction. The label also addresses the risk of Tardive Dyskinesia and severe metabolic changes, such as the development of new-onset diabetes mellitus.

Population-Specific Restrictions

Official safety information contains specific constraints for certain populations. The medicine is not approved for use in older adults with dementia-related psychosis due to a documented increased risk of death and cerebrovascular adverse events (CVAE). Pediatric patients may experience a greater magnitude of weight gain and increases in lipids and prolactin compared to adults.

Overdose and Emergency Response

Overdose and When to Seek Help

A suspected overdose of Onza (olanzapine) requires immediate medical attention due to the risk of severe and potentially fatal outcomes. Regulatory labeling defines the overdose profile primarily through effects on the central nervous and cardiovascular systems.

Documented Clinical Manifestations

Overdose presentations documented in official sources include central nervous system (CNS) depression, ranging from somnolence to coma, along with tachycardia (fast heart rate), slurred speech, agitation, seizures, and respiratory depression. Other noted signs are pupillary changes (mydriasis or miosis) and extrapyramidal symptoms (EPS).

Severe Risks and Required Actions

Fatal outcomes have been reported, with the most severe cases often involving estimated ingestions exceeding 450 mg or the concomitant ingestion of other CNS depressants. Severe physiological risks documented include profound hypotension, cardiac arrhythmias, and potential cardiorespiratory arrest. For all suspected overdoses, the regulatory mandate is to seek immediate medical attention.

Management and Monitoring

Regulatory documents confirm no specific antidote is known for olanzapine overdose. Treatment is strictly symptomatic and supportive. Officially described procedures may include administering activated charcoal or performing gastric lavage shortly after ingestion to reduce absorption. Continuous cardiac monitoring and close medical supervision are essential until the patient fully recovers. Elderly patients are noted to have an increased risk of severe adverse events and mortality, requiring cautious observation.

Therapeutic Uses of Onza

This medication is commonly used across conditions presenting with acute episodes of Schizophrenia and Bipolar I Disorder. The medication is considered relevant in contexts involving heightened systemic burden, and may assist with maintaining functional stability.

Onza is applied across domains where additional symptomatic support is needed, relevant for easing symptoms that may become more disruptive during flare-ups, such as hallucinations, delusions, manic episodes, mixed episodes, and psychomotor agitation. The medication is often used during phases when symptoms become more noticeable and create noticeable functional strain.

“The medication supports patients during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.”


Quick Fact: Symptomatic Support During Episodes

Onza is relevant when short-term symptomatic assistance is appropriate to manage symptoms that may appear suddenly or fluctuate. This use may assist with managing symptoms that interfere with daily comfort, and plays a role in managing conditions involving recurrent or episodic manifestations.

Regulatory References

  1. NIH MedlinePlus overview of Olanzapine

Eligibility and Restrictions for Use

Official Eligibility Profile

Onza is an approved medicine; however, its official regulatory labeling strictly defines the population for whom use is permissible and those for whom it is prohibited or requires special consideration. This profile is governed by official regulatory documents such as the FDA Prescribing Information or the EMA Summary of Product Characteristics (SmPC).


Populations Excluded from Use (Contraindicated)

  • Hypersensitivity: The medicine is strictly contraindicated for use in any individual with a known history of severe hypersensitivity reaction to the active substance or to any of the drug's inactive components (excipients).
  • Specific Clinical States: Use is prohibited in patients with any documented pre-existing medical condition that is explicitly listed as an absolute contraindication in the official label (e.g., certain forms of severe organ impairment or disease states where risk is proven to outweigh benefit).

Eligibility Restrictions

  • Age-Related Rules: The medicine is generally approved only for the population in which it was formally studied. Use in specific age groups, such as the pediatric population (children and adolescents), may be classified as not established unless effectiveness and safety data are explicitly included in the label.
  • Organ Function: Individuals with severe renal or hepatic impairment may be listed as non-eligible or require specialized consideration if the drug's official processing by the body is significantly affected.

Regulatory documentation defines eligible patients as those who possess the condition the drug is indicated for and who do not meet any of the defined contraindication criteria or age-related exclusions.

What should I know about interactions with other medicines?

Onza Interactions with other medicines and products

Official regulatory information describes the interaction profile of Onza (olanzapine) based on metabolic clearance and additive pharmacodynamic effects.

Pharmacokinetic and Metabolic Interactions

Classification Interacting Substance / Category Documented Outcome
CYP1A2 Inhibition Fluvoxamine, Ciprofloxacin Increases olanzapine plasma levels (exposure).
CYP1A2 Induction Carbamazepine, Tobacco Smoking Increases olanzapine clearance, reducing plasma levels.

These interactions necessitate clinical assessment, as substances like Fluvoxamine may require consideration of a lower olanzapine starting dose upon co-administration, while Carbamazepine and Tobacco Smoking may reduce olanzapine concentrations. Activated charcoal reduces the bioavailability of oral olanzapine by over 50%, requiring administration at least 2 hours before or after olanzapine.

Pharmacodynamic Interactions and Restrictions

Co-administration with CNS depressants (including Alcohol) and antihypertensive agents may lead to additive pharmacodynamic effects, such as potentiated sedation or orthostatic hypotension. The official label notes caution when combining olanzapine with other Anticholinergic Drugs or medicines known to increase the QTc interval.

Use of parenteral (Intramuscular) olanzapine is specifically restricted from concomitant administration with Benzodiazepines due to the formally documented risk of severe cardiorespiratory events.

Mechanism of Action

Onza selectively accumulates within the central nervous system (CNS), crossing the blood-brain barrier. Its primary biological target is the GABAA receptor complex, specifically acting as a positive allosteric modulator at the alpha1 and alpha5 subunit interfaces. This interaction induces a conformational change that increases the frequency of chloride ion channel opening upon endogenous GABA binding. The resulting enhanced inward chloride ion flux hyperpolarizes the postsynaptic neuronal membrane, increasing the cell's threshold for action potential generation. Intracellularly, this augmented conductance leads to a downstream cascade of reduced overall neuronal excitability. This specific modulation occurs predominantly in the corticolimbic pathways. The system-level physiological consequence is a generalized decrease in central nervous system activity and a resultant modulation of baseline muscle tone and somatosensory processing.

Dosage and Administration Information

How to Use Onza

Onza (olanzapine) is administered through distinct routes that correspond to the phase of treatment: oral forms for daily maintenance and initiation, and intramuscular (IM) injection forms for either acute rapid stabilization or long-term maintenance.


Dosing and Administration Schedule

Oral administration is typically taken once daily and may be administered without regard to meals as food does not significantly affect absorption. The orally disintegrating tablet (ODT) is designed to dissolve directly on the tongue.

Usage Entity Administration Guideline
Starting Oral Dose Typically 5 mg to 15 mg once daily, depending on the indication (e.g., 5 mg to 10 mg for schizophrenia).
Maximum Daily Dose The maximum recommended daily oral dose is 20 mg.
Dose Adjustment Oral dose adjustments should generally occur at intervals of not less than 24 hours to 1 week, depending on the clinical context.
Acute IM Use The initial short-acting IM dose is typically 10 mg. Subsequent doses may be given with mandated minimum intervals of 2 hours (for the second dose) and 4 hours after the second dose, not to exceed a total of 30 mg within a 24-hour period.

Procedural and Population Adjustments

Specific administration conditions are outlined for the injection forms. The short-acting IM preparation requires reconstitution with Sterile Water for Injection immediately before use. The long-acting IM form is intended for administration only as a deep intramuscular gluteal injection.

Adjustments are specified for certain populations. A lower oral starting dose of 5 mg/day should be considered for individuals over 65 years of age or those with known moderate hepatic impairment. In the event of a missed oral dose, it is generally advised to take it as soon as remembered, unless the time for the next scheduled dose is near.

Recent Clinical Evidence

Research evidence / Overview of Studies for Onza

The research evidence available for Onza (olanzapine), per established scientific record, consists primarily of randomized controlled trials (RCTs), systematic reviews, and longer-term observational studies. This evidence base was developed to examine how the medication relates to outcomes associated with severe mental health conditions. Research focuses on defined time intervals and specific measures to assess symptom patterns and the state of stability.


Evidence for use in Schizophrenia: Acute and Maintenance Treatment

Acute treatment was studied for changes in symptom measurement scales over time in short-term trials. These trials typically observed patients over a four-to-eight-week interval and used standardized rating scales like the PANSS. The findings describe patterns observed in the studies related to measured changes in symptom scores compared to the placebo population. Research exploring long-term symptom patterns monitored the time to documented recurrence or symptom exacerbation, often in trials lasting up to one year or longer. What remains uncertain is the full extent of the long-term outcomes, particularly the relationship between metabolic shifts documented in the trials (such as weight changes and lipid regulation) and the medication’s long-term use; this data is still emerging.


Evidence for use in Bipolar I Disorder: Acute Manic and Maintenance Therapy

Research for Bipolar I Disorder is structured to examine the acute observation of manic or mixed episodes and the longer-term assessment against recurrence. Short-term RCTs were used in research exploring symptom changes during outcomes capturing phases of heightened symptom activity. Maintenance studies reported documented differences in the measured time to recurrence compared to placebo measurements, especially concerning manic relapse. Research provides context on immediate symptom observation for acute agitation (IM formulation) but does not extend to subsequent long-term management.


Research Gaps and Areas of Uncertainty

The research landscape highlights limitations where more study is needed. Long-term outcomes related to metabolic health, such as weight changes and dyslipidemia, are not fully established or characterized by the primary RCT data. The data structure differs across studies, with most long-term findings based on observational cohorts rather than controlled trials. Subgroup findings remain uncertain, and the research provides context but not individual predictions; findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Onza (FAQ)


Q: Is Onza used for the same conditions as other similar drugs?

Olanzapine, the active ingredient in Onza, belongs to a group of medicines known as atypical antipsychotics. Official classifications indicate that drugs in the same pharmacological class are generally used to address similar types of conditions, which involve disturbances in mood and thought regulation.


Q: How quickly should a person expect Onza to start working?

Official product information notes that the medicine reaches steady-state plasma concentration after approximately one week of daily administration. Studies indicate that noticeable improvement in a person's condition can often take anywhere from several days up to a few weeks.


Q: Does Onza need to be taken long-term for it to be effective?

The official prescribing information describes its use for both short-term stabilization (acute treatment) and long-term management (maintenance treatment) of approved conditions. The required duration of use is determined based on the specific condition being addressed.


Q: What is the difference between Onza and its generic name?

The active ingredient in Onza is olanzapine, which is the medicine's generic name. Onza is the specific trade or brand name used by the company that manufactures and markets the product.


Q: Can I take Onza if I am also taking vitamins or supplements?

Regulatory safety information notes the importance of disclosing all supplements and vitamins to the healthcare provider. This is because certain supplements may affect how the drug is metabolized by the body.


Q: What kind of foods or drinks should people be aware of while on Onza?

Regulatory documents specifically advise caution regarding alcohol consumption, as it may increase the medicine's sedative effects. It is also noted that taking activated charcoal significantly lowers the absorption of the oral form. Otherwise, the oral tablets can be taken with or without food.


Q: Do I have to stop taking other medications before starting Onza?

Regulatory guidance states that the healthcare provider should review a patient's entire list of medications before starting this drug. This process is essential to assess for any potential drug interactions or existing conditions that might conflict with its use.


Q: What if I feel like Onza is not working after several weeks?

The timing for assessing the medicine's effectiveness is generally measured in weeks, as clinical improvement takes time. Regulatory information states that if an adjustment is needed, changes to the dose are typically considered after a period of at least one week.


Q: Is it important to stick to a routine when taking Onza?

Regulatory information specifies that the oral medication is typically taken once daily. Adhering to a routine helps maintain stable medication levels in the body, and the official label includes protocol for managing a missed dose.


Q: Does Onza carry a specific boxed warning from regulatory agencies?

Yes, official regulatory documentation includes a Boxed Warning, which is the strongest warning required by the FDA. This warning concerns the increased risk of death and certain adverse events in older adults diagnosed with dementia-related psychosis.


Q: Is Onza considered a controlled substance?

According to regulatory drug databases, Olanzapine is classified as a prescription-only medicine (Rx-only). It is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or similar official bodies.


Q: Are there any common lifestyle changes recommended while taking Onza?

Regulatory safety information advises awareness of risks such as the potential for weight gain and difficulty with body temperature regulation. For instance, official documents note the need to avoid overheating and dehydration, which implies a general awareness of lifestyle practices is needed.


Q: Do the side effects of Onza usually go away after a while?

Official patient information describes a range of possible side effects by how frequently they are documented in studies. Some of these effects are described as potentially temporary, while others may persist, and regulatory guidance suggests that these should be reviewed by a healthcare provider.


Q: Does Onza interact with common over-the-counter pain relievers?

Regulatory labels advise caution when taking this medicine with any other products that might cause sedation or lowering of blood pressure. However, the official interaction list does not include a specific major warning listed for common single-ingredient over-the-counter pain relievers.


Q: Can men and women use Onza the same way?

Regulatory pharmacokinetic data indicates a difference in how long the body takes to process the drug, noting that the elimination half-life is somewhat longer in female subjects. Despite this difference in drug processing, the overall documented safety profile is described as comparable between men and women.


Q: Is Onza a newly developed medication, or has it been around for a long time?

The active ingredient, olanzapine, was first approved by the U.S. Food and Drug Administration (FDA) as an oral formulation in 1996. This approval date indicates the medicine has been available for clinical use for a significant period of time.


Q: Where can I find summaries of the main clinical studies about Onza?

Summaries of clinical studies and trial results supporting the medicine's use are maintained in government-sponsored repositories. These resources include the U.S. National Institutes of Health (NIH) clinical trials database, which is publicly accessible.


Q: Does Onza have a high risk of drug dependency?

Regulatory documentation indicates that this medicine is not classified as a controlled substance. Furthermore, official safety data does not list dependence or addiction as a frequent or common adverse effect of the medicine.


Q: How do the effects of Onza wear off after the last dose?

Official pharmacokinetic documents describe how the drug leaves the body by noting its half-life, which is the time required for the amount of medicine to reduce by half. The half-life for olanzapine is documented to be between 21 and 54 hours.


Q: Can Onza be crushed or split if the pill is too large?

The official patient instructions for the orally disintegrating tablet (ODT) formulation advise that the tablet is not intended to be cut, crushed, or chewed. These tablets must also be used immediately after opening the sealed package.


Q: Is there a patient support program available for people who use Onza?

Official prescribing information for the extended-release injection formulation notes the existence of a Risk Evaluation and Mitigation Strategy (REMS) program. This program is a formal requirement from the FDA to ensure the safe use of the product.


Q: Is Onza known to interact with herbal tea or natural remedies?

While regulatory documents advise general caution with supplements, some patient information specifically notes that the herbal product St. John's Wort may interact with olanzapine. Regulatory information suggests that all herbal and natural remedies be disclosed to the prescriber, as some may affect the drug's metabolism.


Q: How does being pregnant or breastfeeding relate to using Onza?

Official safety documentation indicates that use during pregnancy has not established safety; newborns exposed in the third trimester have been documented as being at risk for specific neurological disturbances or withdrawal symptoms. Furthermore, the drug is documented to be excreted into human milk, and official information generally advises against its use while breastfeeding.


Q: Is Onza available in different strengths?

Yes, the oral tablets are manufactured in multiple strengths to accommodate different prescribing needs. Common available strengths include 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg doses.

How should Onza be stored and disposed of?

The official requirements for storing and disposing of Onza (olanzapine) tablets are set by regulatory agencies to ensure product stability.

Storage Conditions

Requirement Official Regulatory Rule
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F) [1.1].
Protection Keep protected from both light and moisture; do not store in the bathroom [1.2].
Packaging Keep the medication in the container it came in, tightly closed [1.1].
Child Safety Must be stored out of the sight and reach of children [1.2].

Handling and Stability

The Orally Disintegrating Tablet (ODT) form of Onza is sensitive. The ODT must be handled with dry hands and used immediately after opening the sealed blister package, which must be peeled back rather than pushed [1.1, 1.2]. Film-coated tablets stored in an open bottle should be discarded within 6 months [2.4]. Do not use any product past the expiration date [1.1].

Disposal

Unused or expired Onza must be safely discarded. Dispose of the medication in accordance with local requirements, following recommended local drug take-back programs or community guidelines for the disposal of non-flushable medicines [2.4, 2.6].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Onza found in:

A-Z Index: